Dilated cardiomyopathy is a myocardial disease characterised by impaired systolic function and dilatation of the left or both ventricles. The disease is not rare, affecting about one in 2500 individuals' and, despite the development of new treatments, it remains an important cause of mortality and morbidity and is a leading indication for heart transplantation. The cause of dilated cardiomyopathy is generally unknown and the identification of the aetiological and pathogenetic mechanisms underlying the disease is regarded a research priority. 2 An important advance in the search for the aetiology has been the recognition of hereditary transmission in a subset of patients, which indicates that in these cases the origin of the disease must be an altered gene product. The recognition of dilated cardiomyopathy as a genetic disease has clinical implications. Furthermore, the development of molecular genetic techniques has provided the tools for the identification of the gene, or genes, causing the dis- known; positional cloning (or reverse genetics), based on linkage analysis which allows the chromosomal localisation of the disease genes to be mapped; and the positional candidate approach, based on the co-segregation of candidate genes (genes that are candidates for causing the disease) with the disease within families. These approaches have led to impressive advances in the study of primary myocardial diseases during the past few years.
The most frequent form of inherited dilated cardiomyopathy is autosomal dominant FDC which is characterised by development of ventricular dilatation and dysfunction, usually in the second to third decade of life, with progressive heart failure and ventricular arrhythmias. Segregation analysis suggests a monogenic disorder. 4 The premature mortality, the reduced penetrance of the disease, and the absence of early clinical markers have always been serious obstacles in collecting large enough families for molecular genetic studies. Only recently, two research groups reported the results of linkage analysis performed in families with autosomal dominant FDC. First, a single large kindred was studied by our group: affected family members typically had a poorly contracting left ventricle, often associated with ventricular arrhythmias. Strict diagnostic criteria, based on full invasive evaluation of the affected family members, were used to assign clinical status. 2 After many of the candidate genes were excluded, a whole-genome random screening with more than 250 polymorphic markers was undertaken. This allowed the analysis of about 95% of the genome. Linkage of autosomal dominant FDC was eventually found with chromosome 9 (9q13-q22) in this kindred and in two other families6 (fig 1) . A second locus for autosomal dominant FDC was then localised on chromosome lq32 in a large Utah family7 (fig 1) . The analysis of the candidate genes mapping in these regions is currently under investigation.
A rare form of FDC is characterised by autosomal dominant cardiac conduction system disease and later development of myocardial dysfunction (called conduction disease and dilated cardiomyopathy, CDDC). The affected family members manifest arrhythmias and atrioventricular block in the second to third decade of life and a progressive cardiomegaly and heart failure in the fifth to sixth decade. A first linkage study carried out in a single large family from Ohio mapped the CDDC disease gene in the centromere of chromosome 1 (lpl-lql)8 (fig 1) . Recently, in another family of Swiss-German ancestry and similar clinical features, linkage was found with the short arm of chromosome 3 (3p22-p25)9 (fig 1) . The disease genes are unknown and are under investigation.
Till now the only inherited dilated cardiomyopathy for which the disease gene was known is X-linked dilated cardiomyopathy (XLDC), which generally presents in teenage boys as rapidly progressive 
